Moxifloxacin (Avelox®): A novel fluoroquinolone with a broad spectrum of activity

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 3, 2003, Pages 363-370

  Caeiro, Juan Pablo ^a   Iannini, Paul B ^b  

^a DANBURY HOSPITAL   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

Fluoroquinolones; Moxifloxacin; RTI; S. pneumoniae; Toxicity

Indexed keywords

AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTACID AGENT; AZITHROMYCIN; CALCIUM; CEFALEXIN; CEFTRIAXONE; CEFUROXIME AXETIL; CLARITHROMYCIN; CORTICOSTEROID; DIGOXIN; GATIFLOXACIN; GLIBENCLAMIDE; ISONIAZID; ITRACONAZOLE; LANSOPRAZOLE; LEVOFLOXACIN; MOXIFLOXACIN; ORAL CONTRACEPTIVE AGENT; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE; RIFAMPICIN; SOTALOL; SUCRALFATE; THEOPHYLLINE; TROVAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN; VIGAMON; WARFARIN; HETEROCYCLIC COMPOUND; NEW DRUG; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ACHILLES TENDON RUPTURE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MENINGITIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNICABLE DISEASE; CONJUNCTIVITIS; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GRAM NEGATIVE ANAEROBIC BACTERIA; HEART VENTRICLE TACHYCARDIA; HUMAN; KIDNEY FAILURE; LEGIONELLA; LIVER FAILURE; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; QT PROLONGATION; RESPIRATORY TRACT INFECTION; SINUSITIS; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; TENDINITIS; TENDON RUPTURE; TORSADE DES POINTES; TUBERCULOSIS; ANIMAL; CHEMISTRY; REVIEW;

ANIMALS; AZA COMPOUNDS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; FLUOROQUINOLONES; HUMANS; QUINOLINES; RESPIRATORY TRACT INFECTIONS;

EID: 3042699639     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.3.363     Document Type: Article

References (86)

1. Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42, 410-425 (1996).
2. Iannini PB, Kubin R, Reiter C. Over 10 million patients uses: an update on the safety profile of oral moxifloxacin. Am. Soc. Microbiol. CA, USA 346 (2002).
3. Chen DK, McGeer A, de Azavedo JC, Low DE, The Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada. N. Engl. J. Med. 341, 233-239 (1999).
4. Ho PL, Yung RW, Tsang DN et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J. Antimicrob. Chemother. 48, 659-665 (2001).
5. Goldsmith CE, Moore JE, Murphy PG, Ambler JE. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland. J. Antimicrob. Chemother. 41, 420-421 (1998).
6. Resistance of Streptococcus pneumoniae to fluoroquinolones: United States, 1995-1999. MMWR Morb. Mortal. Wkly Rep. 50, 800-804 (2001).
7. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg. Infect. Dis. 9, 1-9 (2003).
8. Kishii R, Takei M, Fukuda H, Hayashi K, Hosaka M. Contribution of the 8-methoxy group to the activity of gatifloxacin against Type II topoisomerases of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47, 77-81 (2003).
9. Marutani K, Matsumoto M, Otabe Y et al. Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light. Antimicrob. Agents Chemother. 37, 2217-2223 (1993).
10. Beyer R, Pestova E, Millichap JJ, Stosor V, Noskin GA, Peterson LR. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin and trovafloxacin efflux. Antimicrob. Agents Chemother. 44, 798-801 (2000).
11. Bearden DT, Danziger LH. Mechanism of action of and resistance to quinolones. Pharmacotherapy 21, S224-S232 (2001).
12. Hooper DC. Bacterial topoisomerases, anti-topoisomerases and anti-topoisomerase resistance. Clin. Infect. Dis. 27(Suppl. 1), S54-S63 (1998).
13. Drlica K, Malik M. Fluoroquinolones: action and resistance. Curr. Top. Med. Chem 3, 249-282 (2003).
14. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. 7, 337-341 (2001).
15. Jones ME, Sahm DF, Martin N et al. Prevalence of gyrA, gyrB, parC and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season. Antimicrob. Agents Chemother. 44, 462-466 (2000).
16. Whitney CG, Farley MM, Hadler J et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N. Engl J. Med. 343, 1917-1924 (2000).
17. Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of BAY 12-8039 on Gram-positive and Gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect. Antimicrob. Agents Chemother. 41, 1377-1379 (1997).
18. Wise R, Andrews JM, Marshall G, Hartman G. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob. Agents Chemother. 43, 1508-1510 (1999).
19. Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmacokinetics, safety and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob. Agents Chemother. 42, 2060-2065 (1998).
20. Muller M, Stass H, Brunner M, Moller JG, Lackner E, Eichler HG. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob. Agents Chemother. 43, 2345-2349 (1999).
21. Pascual A, Garcia I, Ballesta S, Perea EJ. Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. Antimicrob. Agents Chemother. 43, 12-15 (1999).
22. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy 20, 245-256 (2000).
23. Hamamoto K, Shimizu T, Fujimoto N, Zhang Y, Arai S. In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 45, 1908-1910 (2001).
24. Roblin PM, Hammerschlag MR. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 42, 951-952 (1998).
25. Marivitlles M, Kunkel M. Moxifloxacin provides rapid clinical and bactriological resolution of acute exacerbation of chronic bronchitis (AECB): a review of the literature. 10th International Soc. Infectious Dis. (2002).
26. Boswell FJ, Andrews JM, Jevons G, Wise R. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J. Antimicrob. Chemother 50, 495-502 (2002).
27. Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am. J. Respir. Crit. Care Med. 163, 1730-1754 (2001).
28. Landen H, Moller M, Tillotson GS, Kubin R, Hoffken G. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. J. Int. Med. Res. 29, 51-60 (2001).
29. Gehanno P, Darantiere S, Dubreuil C et al. A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. J. Antimicrob. Chemother. 49, 821-826 (2002).
30. Krasemann C, Meyer J. Moxifloxacin (MFX) in acute sinusitis (AS): a bacteriological and clinical meta-analysis. In: Programs and Abstracts of the 9th European Congress of Clinical Microbiology and Infectious Diseases. Taufkirchen, Germany, 139 (1999) (Abstract P204).
31. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Sinus and Allergy Health Partnership. Otolaryngol Head Neck Surg. 123, 5-31 (2000).
32. Blondeau JM. The role of fluoroquinolones in skin and skin structure infections. Am. J. Clin. Dermatol. 3, 37-46 (2002).
33. Behra-Miellet J, Dubreuil L, Jumas-Bilak E. Anti-anaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and β-lactams. Int. J. Antimicrob. Agents 20, 366-374 (2002).
34. Sobottka I, Cachovan G, Sturenburg E et al. In vitro activity of moxifloxacin against bacteria isolated from odontogenic abscesses. Antimicrob. Agents Chemother. 46, 4019-4021 (2002).
35. Hedberg M, Nord CE. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin. Microbiol. Infect. 9, 475-488 (2003).
36. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47, 653-657 (2003).
37. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167, 603-662 (2003).
38. Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J. Chemother. 15, 66-70 (2003).
39. Gomez-Rodriguez J, Ruiz-Serrano M, Cuevas O et al. Comparative in vitro activity of moxifloxacin and linezolid with other agents against significant rapidly growing mycobacteria. Am. Soc. Microbiol. 156 (2002).
40. Cottagnoud P, Tauber MG. Fluoroquinolones in the treatment of meningitis. Curr. Infect. Dis. Rep. 5, 329-336 (2003).
41. Ostergaard C, Sorensen TK, Knudsen JD, Frimodt-Moller N. Evaluation of moxifloxacin, a new 8-methoxyquinotone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob. Agents Chemother. 42, 1706-1712 (1998).
42. Rodriguez-Cerrato V, McCoig CC, Saavedra J et al. Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci. Antimicrob. Agents Chemother. 47, 211-215 (2003).
43. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am. J. Ophthalmol. 133, 463-466 (2002).
44. Garcia-Saenz MC, Arias-Puente A, Fresnadillo-Martinez MJ, Carrasco-Font C. Human aqueous humor levels of oral ciprofloxacin, levofloxacin and moxifloxacin. J. Cataract Refract. Surg. 27, 1969-1974 (2001).
45. Hoogkamp-Korstanje JA, Roelofs-Willemse J. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates. J. Antimicrob. Chemother. 45, 31-39 (2000).
46. Hoppe JE, Dalhoff A, Pfrunder D. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin and ciprofloxacin. Antimicrob. Agents Chemother. 42, 1868 (1998).
47. Di Caro S, Ojetti V, Zocco MA et al. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol. Ther. 16, 527-532 (2002).
48. Dong Y, Zhao X, Domagala J, Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 43, 1756-1758 (1999).
49. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl. 3), S147-156 (2001).
50. Blondeau. JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45, 433-438 (2001).
51. Iannini PB, Mandell LA. An updated safety profile of moxifloxacin. J. Chemother. 14(Suppl. 2), 29-34 (2002).
52. Man I, Murphy J, Ferguson J. Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers. J. Antimicrob. Chemother. 43(Suppl. B), 77-82 (1999).
53. Schmuck G, Schurmann A, Schluter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob. Agents Chemother. 42, 1831-1836 (1998).
54. Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy 47(Suppl. 3), 9-14 (2001); discussion 44-48 (2001).
55. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol. Pharmacol. 59, 122-126 (2001).
56. Iannini PB, Kubin R, Reiter C, Tillotson G. Reassuring safety profile of moxifloxacin. Clin. Infect. Dis. 32, 1112-1114 (2001).
57. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 289, 2120-2127 (2003).
58. Baden LR, Horowitz G, Jacoby H, Eliopoulos GM. Quinolones and false-positive urine screening for opiates by immunoassay technology. JAMA 286, 3115-3119 (2001).
59. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. Br. Med. J. 324, 1306-1307 (2002).
60. Chhajed PN, Plit ML, Hopkins PM, Malouf MA, Glanville AR. Achilles tendon disease in lung transplant recipients: association with ciprofloxacin. Eur. Respir. J. 19, 469-471 (2002).
61. Gabutti L, Stoller R, Marti HP. [Fluoroquinolones as etiology of tendinopathy]. Ther. Umsch 55, 558-561 (1998).
62. Aros C, Flores C, Mezzano S. [Achilles tendinitis associated to levofloxacin: report of 4 cases]. Rev. Med. Child. 130, 1277-1281 (2002).
63. Shinohara YT, Tasker SA, Wallace MR, Couch KE, Olson PE. What is the risk of Achilles tendon rupture with ciprofloxacin? J. Rheumatol. 24, 238-239 (1997).
64. Ortiz-De-Saracho J, Pantoja L, Romero MJ, Lopez R. Moxifloxacin-induced Clostridium difficile diarrhea. Ann. Pharmacother. 37, 452-453 (2003).
65. Stass H, Kubitza D. Profile of moxifloxacin drug interactions. Clin. Infect. Dis. 32(Suppl. 1), S47-S50 (2001).
66. Andriole VT, Haverstock D, Choudhri S, Church D. Safety of moxifloxacin (MXF) in the elderly. Am. Soc. Microbiol. 348 (2002).
67. Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 20, 289-302 (2003).
68. Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Clin. Pharmacokinet. 40(Suppl. 1), 39-48 (2001).
69. Stass H, Kubitza D. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin. Pharmacokinet. 40(Suppl. 1), 33-38 (2001).
70. Stass H, Kubicza D. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. Clin. Pharmacokinet. 40(Suppl. 1), 57-62 (2001).
71. Stass H, Schuhly U, Moller JG, Delesen H. Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin. Pharmacokinet. 40(Suppl. 1), 49-55 (2001).
72. Stass H, Kubitza D. Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone and theophylline. Clin. Pharmacokinet. 40(Suppl. 1), 63-70 (2001).
73. Stass H, Kubitza D, Halabi A, Delesen H. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br. J. Clin. Pharmacol. 53, 232-237 (2002).
74. Stass H, Dammer S, Kubitza D, Moeller J, Delesen H, Schaefers R. No dose adjustment is needed for patients undergoing hemodialysis (HD) receiving oral moxifloxacin (MFX). Am. Soc. Microbiol. (2002).
75. Stass H, Dammer S, Kubirza D, Moeller J, Delesen H, Schaefers R. Am. Soc. Microbiol. (2002).
76. Krasemann C, Meyer J, Tillotson G. Evaluation of the clinical microbiology profile of moxifloxacin. Clin. Infect. Dis. 32(Suppl. 1), S51-S63 (2001).
77. Fogarty C, Choudhri S, Herrington J et al. Moxifloxacin in the treatment of community-acquired pneumonia associated with drug-resistant Streptococcus pneumoniae. (2002) (Abstract 169).
78. Goldstein EJ. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone and desfluoroquinolone therapeutic agents. Clin. Infect. Dis. 35, S106-S111 (2002).
79. Lachand AT, Lee BL, Padula AM et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N. Engl. J. Med. 325, 520-521 (1991).
80. Brueggemann AB, Coffman SL, Rhomberg P et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob. Agents Chemother. 46, 680-688 (2002).
81. Parish LC, Routh HB, Miskin B et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int. J. Clin. Pract. 54, 497-503 (2000).
82. Leal del Rosal P, Martinez R, Fabian Gea. Efficacy and safety of moxifloxacin vs. cephalexin in the treatment of mild to moderate uncomplicated skin and soft tissue infections. 21st Internat. Congress Chemother. (1999) (Abstract no. P493).
83. Siegert R, Gehanno P, Nikolaidis P et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir. Med. 94, 337-344 (2000).
84. Arrieta J, Galgano, A, Sakano E. Safety and efficacy of moxifloxacin (MFX) vs. Amoxicillin/Clavulanate (AMC) in the treatment of acute sinusitis. (2001).
85. Klossek JM, Siegert R, Nikolaidis P, Arvis P, Leberre MA. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults. J. Laryngol. Otol. 117, 43-51 (2003).
86. Rakkar S, Roberts K, Towe BF, Flores SM, Heyd A, Warner J. Moxifloxacin versus amoxicillin clavulamte in the treatment of acute maxillary sinusitis: a primary care experience. Int. J. Clin. Pract. 55, 309-315 (2001).